CRISPR技术:全球市场
市场调查报告书
商品编码
1578155

CRISPR技术:全球市场

CRISPR Technology: Global Markets

出版日期: | 出版商: BCC Research | 英文 122 Pages | 订单完成后即时交付

价格

全球CRISPR技术市场规模预计将从2023年的34亿美元和2024年的38亿美元成长到2029年终的75亿美元,在预测期内复合年增长率为14.4%。

从应用来看,药物开发产业预计将从2024年的19亿美元成长到2029年的38亿美元,复合年增长率为15.5%。农业部门预计将从 2024 年的 10 亿美元成长到 2029 年的 20 亿美元,复合年增长率为 14.2%。

本报告调查了全球 CRISPR 技术市场,并提供了市场概况、市场影响因素和市场机会、法律制度、新兴技术和技术发展趋势、市场规模趋势和预测以及各个细分市场和地区的分析。了详细分析、竞争格局、主要企业概况等。

目录

第一章执行摘要

  • 市场展望
  • 调查范围
  • 市场概况

第二章 市场概况

  • 基因组编辑
  • CRISPR
  • CRISPR 组件
  • 作用机制
  • CRISPR基因编辑工作流程
  • CRISPR技术的优点和缺点
  • 价格分析
  • PESTLE分析
  • 波特五力分析
  • 监管状态:按类型
  • 人类
  • 基因驱动
  • 农业
  • 动物
  • 监管状况:按地区
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他领域

第三章市场动态

  • 市场动态简介
  • 市场驱动因素
  • 慢性病发生率上升
  • 遗传疾病的盛行率
  • 政府和私人资金
  • 市场限制因素
  • 替代技术
  • 市场机会
  • 申请数量增加
  • 市场挑战
  • 复杂且不断变化的监管环境
  • 基于 CRISPR 的治疗高成本

第四章新兴科技与发展

  • 新兴技术
  • CRISPR 的体内递送
  • 改进的Cas变体
  • AI
  • 临床试验分析
  • 临床试验分析(按研究类型)
  • 临床试验分析(按状态)
  • 临床试验分析(按阶段)
  • 临床试验
  • 专利分析
  • 专利(按年份)
  • 专利(按申请人)
  • 专利(按主要所有者)
  • 专利(按司法管辖区)
  • 智慧财产权纠纷/专利问题

第五章市场区隔分析

  • 细分细分
  • 市场区隔:按应用
  • 药物开发
  • 农业
  • 诊断
  • 其他的
  • 市场区隔:按最终用户
  • 生物技术和製药公司
  • 学术/政府研究院
  • CRO
  • 地域分布
  • 市场区隔:按地区
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他领域

第六章 竞争讯息

  • 市场分析
  • 战略分析

第7章 CRISPR技术的永续性:ESG视角

  • ESG:简介
  • CRISPR 技术的永续性:ESG 视角
  • ESG 关键议题
  • CRISPR技术的ESG效能分析
  • 环境绩效
  • 社会表现
  • 管治绩效
  • BCC的结语

第8章附录

  • 调查方法
  • 参考
  • 简称
  • 公司简介
  • AGILENT TECHNOLOGIES INC.
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • DANAHER CORP.
  • EDITAS MEDICINE
  • GENSCRIPT
  • INTELLIA THERAPEUTICS INC.
  • LONZA
  • MERCK KGAA
  • THERMO FISHER SCIENTIFIC INC.
Product Code: HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

The global market for CRISPR technology in drug development application is expected to grow from $1.9 billion in 2024 to $3.8 billion by 2029, at a CAGR of 15.5% from 2024 to 2029.

The global market for CRISPR technology in agriculture application is expected to grow from $1.0 billion in 2024 to $2.0 billion by 2029, at a CAGR of 14.2% from 2024 to 2029.

Report Scope

This report on CRISPR technology provides market projections for 2029 and analyzes the market for CRISPR technology by application and end user. Applications covered include drug development, agriculture, diagnostics and others. End users include biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations.

Report Includes

  • 32 data tables and 61 additional tables
  • An analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
  • Analyses of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
  • Discussion of the market potential for CRISPR technology
  • Estimate of the market size and a revenue forecast for the global CRISPR technology market, and a corresponding market share analysis by application, end user, and region
  • Discussion of the major market dynamics, regulations, industry challenges, and macroeconomic factors that will affect the demand for CRISPR technology market over the next five years
  • A look at the recent breakthrough in CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
  • A comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
  • Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
  • A discussion on ESG challenges and ESG practices of the industry participants
  • A look at the proprietary technologies and strategic alliances of the companies best positioned in the CRISPR market
  • Analysis of the industry structure, competitive landscape, clinical trials, ongoing research activities, and the impact of COVID-19
  • Company profiles of the major players, including Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics and Danaher Corp.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Genome Editing
  • CRISPR
  • Introduction
  • Components of CRISPR
  • Mechanism of Action
  • CRISPR Gene Editing Workflow
  • Advantages and Disadvantages of CRISPR Technology
  • Pricing Analysis
  • PESTLE Analysis
  • Porter's Five Forces Analysis
  • Regulatory Landscape, by Type
  • Human
  • Gene Drives
  • Agriculture
  • Animals
  • Regulatory Landscape, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 3 Market Dynamics

  • Market Dynamics Snapshot
  • Market Drivers
  • Rising Incidence of Chronic Diseases
  • Prevalence of Genetic Disorders
  • Government and Private Funding
  • Market Restraints
  • Alternative Technologies
  • Market Opportunities
  • Increase in the Number of Applications
  • Market Challenges
  • Complex and Evolving Regulatory Landscape
  • High Cost of CRISPR-based Therapy

Chapter 4 Emerging Technologies and Developments

  • Emerging Technologies
  • In Vivo Delivery of CRISPR
  • Improved Cas Variants
  • Artificial Intelligence
  • Clinical Trials Analysis
  • Clinical Trials Analysis, by Type of Study
  • Clinical Trials Analysis, by Status
  • Clinical Trials Analysis, by Phase
  • Clinical Trials
  • Patent Analysis
  • Patents, by Year
  • Patents, by Top Applicant
  • Patents, by Top Owner
  • Patents, by Jurisdiction
  • Intellectual Property Disputes and Patent Issues

Chapter 5 Market Segmentation Analysis

  • Segmentation Breakdown
  • Market Breakdown, by Application
  • Drug Development
  • Agriculture
  • Diagnostics
  • Other Applications
  • Market Breakdown, by End User
  • Biotech and Pharmaceutical Companies
  • Academics and Government Research Institutes
  • Contract Research Organizations
  • Geographic Breakdown
  • Market Analysis, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Market Analysis
  • Strategic Analysis

Chapter 7 Sustainability in CRISPR Technology: An ESG Perspective

  • Introduction to ESG
  • Sustainability in CRISPR Technology: An ESG Perspective
  • Key ESG Issues
  • CRISPR Technology ESG Performance Analysis
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks from BCC

Chapter 8 Appendix

  • Methodology
  • References
  • Abbreviations
  • Company Profiles
  • AGILENT TECHNOLOGIES INC.
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • DANAHER CORP.
  • EDITAS MEDICINE
  • GENSCRIPT
  • INTELLIA THERAPEUTICS INC.
  • LONZA
  • MERCK KGAA
  • THERMO FISHER SCIENTIFIC INC.

List of Tables

  • Summary Table : Global Market for CRISPR Technology, by Application, Through 2029
  • Table 1 : Comparison of Genome Editing Techniques
  • Table 2 : Comparison of sgRNA Formats
  • Table 3 : Comparison of Cas Enzymes
  • Table 4 : Pricing Analysis of CRISPR Technology Products, by Company
  • Table 5 : Regulatory Rating: Human Gene Editing, by Country/Region
  • Table 6 : Regulatory Rating: Gene Drives, by Country/Region
  • Table 7 : Regulatory Rating: Crops/Food, by Country/Region
  • Table 8 : Regulatory Rating: Animals, by Country/Region
  • Table 9 : Regulatory Landscape in Asia-Pacific Countries
  • Table 10 : Regulatory Landscape in South American Countries
  • Table 11 : Chronic Diseases: Applications of CRISPR-based Therapy
  • Table 12 : Genetic Disease: CRISPR-based Therapy
  • Table 13 : CRISPR Technology: Venture Funding, 2021-2024
  • Table 14 : Clinical Trials in CRISPR Technology, by Type of Study, August 2024
  • Table 15 : Clinical Trials in CRISPR Technology, by Status, August 2024
  • Table 16 : Clinical Trials in CRISPR Technology, by Phase, August 2024
  • Table 17 : Select Clinical Trials, 2024
  • Table 18 : Patents Granted on CRISPR Technology, by Top Applicant, 2020-2023
  • Table 19 : Patents Granted on CRISPR Technology, by Top Owner, 2020-2023
  • Table 20 : Patents Granted on CRISPR Technology, by Jurisdiction, 2020-2023
  • Table 21 : Global Market for CRISPR Technology, by Application, Through 2029
  • Table 22 : CRISPR-Based Genetic Therapy: Pipeline, 2024
  • Table 23 : Global Market for Drug Development in CRISPR Technology, by Region, Through 2029
  • Table 24 : CRISPR-Edited Crops
  • Table 25 : Global Market for Agriculture in CRISPR Technology, by Region, Through 2029
  • Table 26 : CRISPR-based Diagnostics
  • Table 27 : Global Market for Diagnostics in CRISPR Technology, by Region, Through 2029
  • Table 28 : Global Market for Other Applications in CRISPR Technology, by Region, Through 2029
  • Table 29 : Global Market for CRISPR Technology, by End User, Through 2029
  • Table 30 : Biotech and Pharmaceutical Partners of CRISPR Technology Companies
  • Table 31 : Recent Collaborations Among Biotech, Pharma and CRISPR Technology Firms, 2023-2024
  • Table 32 : Global Market for Biotech and Pharma Companies for CRISPR Technology, by Region, Through 2029
  • Table 33 : Global Market for Academics and Government Research Institutes for CRISPR Technology, by Region, Through 2029
  • Table 34 : Global Market for CRO for CRISPR Technology, by Region, Through 2029
  • Table 35 : Global Market for CRISPR Technology, by Region, Through 2029
  • Table 36 : North American Market for CRISPR Technology, by Country, Through 2029
  • Table 37 : European Market for CRISPR Technology, by Country, Through 2029
  • Table 38 : Asia-Pacific Market for CRISPR Technology, by Country, Through 2029
  • Table 39 : Leading Companies in the CRISPR Technology Market
  • Table 40 : Small and Medium-Sized Companies in the CRISPR Technology Market
  • Table 41 : Recent Developments in the CRISPR Technology Market, 2022-2024
  • Table 42 : Bioethical Issues and Risks Associated with CRISPR Technology
  • Table 43 : ESG Rankings for CRISPR Technology Companies, 2024*
  • Table 44 : ESG: Environmental Overview
  • Table 45 : ESG: Social Overview
  • Table 46 : ESG: Governance Overview
  • Table 47 : Information Sources in this Report
  • Table 48 : Abbreviations Used in this Report
  • Table 49 : Agilent Technologies Inc.: Company Snapshot
  • Table 50 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
  • Table 51 : Agilent Technologies Inc.: Product Portfolio
  • Table 52 : Agilent Technologies Inc.: News/Key Developments, 2021
  • Table 53 : Beam Therapeutics: Company Snapshot
  • Table 54 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 55 : Beam Therapeutics: Product Portfolio
  • Table 56 : Beam Therapeutics: News/Key Developments, 2021-2023
  • Table 57 : Caribou Biosciences Inc.: Company Snapshot
  • Table 58 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
  • Table 59 : Caribou Biosciences Inc.: Product Portfolio
  • Table 60 : Caribou Biosciences Inc.: News/Key Developments, 2021-2023
  • Table 61 : CRISPR Therapeutics: Company Snapshot
  • Table 62 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 63 : CRISPR Therapeutics: Product Portfolio
  • Table 64 : CRISPR Therapeutics: News/Key Developments, 2022-2024
  • Table 65 : Danaher Corp.: Company Snapshot
  • Table 66 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 67 : Danaher Corp.: Product Portfolio
  • Table 68 : Danaher Corp.: News/Key Developments, 2021-2024
  • Table 69 : Editas Medicine: Company Snapshot
  • Table 70 : Editas Medicine: Financial Performance, FY 2022 and 2023
  • Table 71 : Editas Medicine: Product Portfolio
  • Table 72 : Editas Medicine: News/Key Developments, 2022 and 2023
  • Table 73 : GenScript: Company Snapshot
  • Table 74 : GenScript: Financial Performance, FY 2022 and 2023
  • Table 75 : GenScript: Product Portfolio
  • Table 76 : GenScript: News/Key Developments, 2021
  • Table 77 : Intellia Therapeutics Inc.: Company Snapshot
  • Table 78 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
  • Table 79 : Intellia Therapeutics Inc.: Product Portfolio
  • Table 80 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2023
  • Table 81 : Lonza: Company Snapshot
  • Table 82 : Lonza Financial Performance, FY 2022 and 2023
  • Table 83 : Lonza: Product Portfolio
  • Table 84 : Lonza: News/Key Developments, 2022-2024
  • Table 85 : Merck KGaA: Company Snapshot
  • Table 86 : Merck KGaA: Financial Performance, FY 2022 and 2023
  • Table 87 : Merck KGaA: Product Portfolio
  • Table 88 : Merck KGaA: News/Key Developments, 2021
  • Table 89 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 90 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 91 : Thermo Fisher Scientific Inc: Product Portfolio
  • Table 92 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022

List of Figures

  • Summary Figure : Global Market for CRISPR Technology, by Application, 2021-2029
  • Figure 1 : CRISPR: Mechanism of Action
  • Figure 2 : CRISPR Gene Editing: Workflow
  • Figure 3 : Advantages and Disadvantages of CRISPR Technology
  • Figure 4 : PESTLE Analysis - CRISPR Technology
  • Figure 5 : Market Dynamics of CRISPR Technology
  • Figure 6 : Estimated Numbers of All Cancer Cases, Both Sexes, 2022-2050
  • Figure 7 : Global Estimates: People with Diabetes (20 to 79), 2021-2045
  • Figure 8 : Emerging Trends/Technologies in the CRISPR Technology Market
  • Figure 9 : Patents Granted on CRISPR Technology, by Year, 2020-2022
  • Figure 10 : Global Market Shares for CRISPR Technology, by Application, 2023
  • Figure 11 : CRISPR Technology in Drug Development
  • Figure 12 : Uses of CRISPR in Agriculture
  • Figure 13 : Global Market Shares for CRISPR Technology, by End User, 2023
  • Figure 14 : Number of Scientific Publications on CRISPR, by Year, 2020-2023
  • Figure 15 : Global Market Shares for CRISPR Technology, by Region, 2023
  • Figure 16 : North American Market Shares of CRISPR Technology, by Country, 2023
  • Figure 17 : U.S. Market for CRISPR Technology, 2021-2029
  • Figure 18 : Canadian Market for CRISPR Technology, 2021-2029
  • Figure 19 : European Market Shares of CRISPR Technology, by Country, 2023
  • Figure 20 : German Market for CRISPR Technology, 2021-2029
  • Figure 21 : U.K. Market for CRISPR Technology, 2021-2029
  • Figure 22 : French Market for CRISPR Technology, 2021-2029
  • Figure 23 : Rest of the European Market for CRISPR Technology, 2021-2029
  • Figure 24 : Asia-Pacific Market Shares of CRISPR Technology, by Country, 2023
  • Figure 25 : Chinese Market for CRISPR Technology, 2021-2029
  • Figure 26 : Japanese Market for CRISPR Technology, 2021-2029
  • Figure 27 : Indian Market for CRISPR Technology, 2021-2029
  • Figure 28 : Rest of Asia-Pacific Market for CRISPR Technology, 2021-2029
  • Figure 29 : RoW Market for CRISPR Technology, 2021-2029
  • Figure 30 : Pillars of ESG
  • Figure 31 : Advantages of ESG for Companies
  • Figure 32 : Methodology Used in the CRISPR Technology Market
  • Figure 33 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 34 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2023
  • Figure 35 : Caribou Biosciences Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 36 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 37 : Danaher Corp.: Market Share, by Business Unit, FY 2023
  • Figure 38 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 39 : GenScript: Revenue Share, by Business Unit, FY 2023
  • Figure 40 : GenScript: Revenue Share, by Country/Region, FY 2023
  • Figure 41 : Lonza: Revenue Share, by Business Unit, FY 2023
  • Figure 42 : Lonza: Revenue Share, by Country/Region, FY 2023
  • Figure 43 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
  • Figure 44 : Merck KGaA: Revenue Share, by Region, FY 2023
  • Figure 45 : Thermo Fisher Scientific Inc.: Market Share, by Business Unit, FY 2023
  • Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, FY 2023